Plant breeding plays a vital role in ensuring global food security by increasing crop yields, improving nutritional quality ...

We expect investors to focus on the sales numbers of CRISPR Therapeutics’ CRSP sole-marketed product, Casgevy, and other ...

Bristol Myers Squibb’s new treatment for schizophrenia didn’t provide additional benefits to patients when given on top of ...

Gene therapy developer CRISPR Therapeutics AG (CRSP) is navigating some regulatory and commercial dynamics. Its flagship gene ...

An expert panel will discuss the latest research on CRISPR and how to use it in biotechnology and disease research.

Endpoints Weekly covers Q1 earnings from major pharma companies, with focus on tariff concerns. FDA's Makary discusses new rare disease pathway, and HuidaGene reports first brain CRISPR treatment.

Genome editing has advanced at a rapid pace with promising results for treating genetic conditions—but there is always room ...

Chinese biotech HuidaGene reports early success with first CRISPR brain treatment in 9-year-old with MECP2 duplication ...

Genome editing has advanced at a rapid pace with promising results for treating genetic conditions-but there is always room for improvement.

Genome editing has advanced at a rapid pace with promising results for treating genetic conditions -- but there is always room for improvement. A new paper showcases the power of scalable protein ...

Latest study leverages new constructs for nuclear localization signal (NLS) sequences to improve editing efficiency in human ...

In the latest trading session, CRISPR Therapeutics AG (CRSP) closed at $39.11, marking a +1.48% move from the previous day. Gene therapy developer CRISPR Therapeutics AG (CRSP) is navigating some ...